Abstract
CB2 cannabinoid receptor agonists hold promise as a new class of therapeutics for indications as diverse as pain, neuroinflammation, immune suppression and osteoporosis. These potential indications are supported by strong preliminary data from multiple investigators using diverse preclinical models. However, clinical trials for CB2 agonists, when they have been reported have generally been disappointing. This review considers possible explanations for the mismatch between promising preclinical data and disappointing clinical data. We propose that a more careful consideration of CB2 receptor pharmacology may help move CB2 agonists from "promising" to "effective" therapeutics.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 16-20 |
| Number of pages | 5 |
| Journal | Progress in Neuro-Psychopharmacology and Biological Psychiatry |
| Volume | 38 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jul 2 2012 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cannabinoid
- Drug development
- Functional selectivity
- Tolerance
Fingerprint
Dive into the research topics of 'CB2: Therapeutic target-in-waiting'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS